Business & Finance14 January 2025, 2:12 pm 1 minute
Reuters was two-and-a-half minutes ahead of rivals on Eli Lilly’s unscheduled trading update, which showed fourth-quarter sales of its weight-loss drug Zepbound would miss Wall Street estimates. The drugmaker’s shares slumped 8% on the news.
Article TagsTopics of Interest: Business & FinanceType: Reuters BestSectors: Business & FinanceRegions: AmericasWin Types: SpeedStory Types: Exclusive / ScoopMedia Types: TextCustomer Impact: Important Regional Story
A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. ReutersPrescription fills for...
The Pakistan Stock Exchange (PSX) achieved a historic milestone on Tuesday, surpassing the 111,000-point mark for the first time, propelled by strong macroeconomic...
Last Updated:December 10, 2024, 12:52 ISTRevenue Secretary Sanjay Malhotra will replace Shaktikanta Das as the 26th Governor of RBIShaktikanta Das will demit office today...
A real-life "Succession" battle for Rupert Murdoch's media empire has ended with a Nevada court commissioner denying the billionaire's bid to change a family...